Roche MCOE will provide physicians and patients with advanced molecular technologies including Roche’s cobas 4800 BRAF V600 Mutation Test to identify patients who are eligible for treatment with the drug Zelboraf (vemurafenib) used for inoperable or metastatic melanoma.

The collaboration aims Cedars-Sinai to bring together many existing initiatives related to personalized medicine diagnostics, as well as a newly created Advanced Biorepository and Morphology Translational Core.

Cedars-Sinai Medical Center department of pathology and laboratory medicine chair Mahul Amin said this relationship provides excellent synergy with their vision to be a premier academic medical center in personalized medicine through translational research for the best patient outcome.